Measles Initiative Management and Financing September 13, 2011

Overview

 MI management and finance mechanism – strengths and challenges  Financial update

MI Process

Reporting Monitoring and evaluation Management Review, consolidate and prioritize Implementation 0 Disbursement Fundraising

Management - Strengths

 Country driven  No secretariat  Flexible  Transparent  Defined roles and responsibilities: with shared responsibility and credit  Well coordinated: avoids programme fragmentation  Clearly defined monitoring and evaluation indicators and process  Accountable: accurate & detailed reporting of results & resources on annual basis

Management

Challenge Tactic

 Balance needs of each partner agency with needs of the MI  MI communication/advocacy support hired  MI branded communication tools – MI.org, Facebook, Twitter, Storify, etc.

Challenge

 Raise awareness of partnership and goals

Management

Tactic

 Advocacy survey – Inform direction of MI advocacy team  MI advocacy team (MIAT) – Finalizing TORs, structure and management, short-term workplan

ARC

Financial Mechanism

CDC UNF (matching funds) “The Measles Fund” Other Donors UNFIP WHO/HQ WHO/Country Operational Costs, Technical Assistance, and Lab/Surveillance UNICEF/NY UNICEF/Country

(Donor Partners)

UNICEF/Supply Vaccine/ Syringes

(UN Partners)

ICC Country Plans

MOH, Red Cross/Crescent Societies, Lions, LDS and other NGOs

(In-Country Partners)

Note: Funds are released when ICC-approved country plans are approved by partners.

Financial Mechanism - Strengths

 Flexible  Rapid and full disbursement of funds  Able to balance WHO and UNICEF funding needs in different settings  Low overhead costs  Low transaction costs for donors, partners and countries (one pooled donor fund, one proposal, one report)  Streamlined: joint resource mobilization

Financial Mechanism



Challenge

Decline in funds available Measles Initiative Annual Donations, 2001-2011*

180 160 140 120 100 80 60 40 20 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Donations

*Excluding country contributions

Tactic

 Additional resource mobilization support – TORS developed, interviews underway  New partners  Measles mortality reduction investment case (Dec. 2011)  Eradication investment case (Apr. 2012)  High net worth individuals investment case (near final)

Financial Mechanism

Challenge

 Large outbreaks that require emergency ORI – $30m in 2010 and in 2011

Tactic

 Sufficient funds for high quality preventative campaigns Measles Case Distribution by Month, Sub-Saharan Africa 2006-2010  Ongoing discussions regarding outbreak response fund  Coordination with other humanitarian agencies

Financial Mechanism

Challenge

 Non-binding agreement with countries to finance 50% of SIA costs

1.80

1.60

1.40

1.20

1.00

0.80

0.60

~ 50% of ops costs (USD 0.32 per child) 0.40

0.20

0.00

C A D R R C on go To go M M al ad i ag ascar Senegal N ig er Eth io pi a C omo ro s Gh an a M al awi Le so th o Za mb ia C on go N ig er ia Zi mb ab we Swaz ilan d South A fr ica

Tactic

 On-going discussions with GAVI and other partners to explore common standards for implementing country co-financing  MI advocacy team to focus on raising political and financial commitment from implementing countries

Financial Update

Historic Measles Initiative Support

 Technical – – Vaccination and surveillance strategies Program planning, implementation, M and E  Financial – – Bundled vaccine SIA operational costs • 100% catch-up campaigns • 50% for follow-up campaigns – – Lab and surveillance Technical assistance  Advocacy and communication

Additional Cost Elements to Achieve Goals

 Research  Outbreak response  Routine – Scale up of MCV1 – MCV2 introduction  Rubella – Catch-up campaigns – Introduction into routine

Annual Donations 2001-2011 and Financial Resource Requirements, Projections, Funding Gap 2012

180 Funding Gap 2012: $43.4 million 160 140 120 100 80 60 40 20 0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Donations Projected Donations Funding Gap

* Excluding country contributions

External Contributions, Projected Contributions and Funding Gap for 2001-2012

Total: $987 million (excluding country contributions for follow-up SIAs, & intro. of MCV2) UNICEF IFFIm UNF** ARC* CIDA

2012 funding gap US$43.4 m

CDC GAVI Merck Japan BMGF Norway LDS *includes ARC and partners: ARC chapter contributions, Anne Ray Charitable Trust, BD, Herman and Katherine Peters Foundation, and others ** includes UNF and partners

Next Steps

 Financial resource requirements, 2011-2015  Measles eradication investment case – – global burden of disease expected benefits, risks, and costs of the eradication and comparator options (i.e., control) – – – – – social, political, and economic challenges ethical considerations operational and other research needs

different financial instruments and funding mechanisms options for management and governance

Anne Ray Charitable Trust